Keeping Pace: Emerging Treatment Considerations in Metastatic Urothelial Cancer - a podcast by ReachMD

CME credits: 0.25

Valid until: 10-04-2021

Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-emerging-treatment-considerations-metastatic-urothelial-cancer/11388/

The treatment of urothelial carcinoma, the most common type of bladder cancer, has historically been limited to platinum-based chemotherapy; however, the majority of patients will relapse. And while immunotherapy has offered survival benefits to patients, not all patients respond to immune checkpoint inhibitors. That’s why it’s so important for clinicians to understand the current and emerging treatment strategies for patients with metastatic urothelial cancer, as this activity explains.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD